EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial

Khaled Ezzedine, Elena Peeva, Yuji Yamaguchi, Lori Ann Cox, Anindita Banerjee, George Han, Iltefat Hamzavi, Anand K Ganesan, Mauro Picardo, Diamant Thaçi, John E Harris, Jung Min Bae und 8 weitere

Journal of the American Academy of Dermatology · 2023-02 · 88 (2) · 395-403

DOI: 10.1016/j.jaad.2022.11.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2023-02. Verfasst von Khaled Ezzedine und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hôpital Henri Mondor and Université Paris-Est Créteil, EpiDermE - Epidemiology in Dermatology and Evaluation of Therapeuti…. Hauptthemen laut MEDLINE: Vitiligo. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc Centers for Therapeutic Innovation, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. OBJECTIVE: To evaluate the efficacy and safety of ritlecitinib, an oral JAK3 (Janus kinase)/TEC (tyrosine kinase expressed in hepatocelluar carcinoma) inhibitor, in patients with active nonsegmental vitiligo in a phase 2b trial (NCT03715829). METHODS: Patients were randomized to once-daily oral ritlecitinib ± 4-week loading dose (200/50 mg, 100/50 mg, 30 mg, or 10 mg) or placebo for 24 weeks (dose-ranging period). Patients subsequently received ritlecitinib 200/50 mg daily in a 24-week extension period. The primary efficacy endpoint was percent change from baseline in Facial-Vitiligo Area Scoring Index at week 24. RESULTS: A total of 364 patients were treated in the dose-ranging period. Significant differences from placebo in percent change from baseline in Facial-Vitiligo Area Scoring Index were observed for the ritlecitinib 50 mg groups with (-21.2 vs 2.1; P < .001) or without (-18.5 vs 2.1; P < .001) a loading dose and ritlecitinib 30 mg group (-14.6 vs 2.1; P = .01). Accelerated improvement was observed after treatment with ritlecitinib 200/50 mg in the extension period (n = 187). No dose-dependent trends in treatment-emergent or serious adverse events were observed across the 48-week treatment. LIMITATIONS: Patients with stable vitiligo only were excluded. CONCLUSIONS: Oral ritlecitinib was effective and well tolerated over 48 weeks in patients with active nonsegmental vitiligo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoHumansDouble-Blind MethodSkinJanus KinasesProtein Kinase InhibitorsChronic DiseaseTreatment Outcome

Stichwörter der Autor:innen

JAK inhibitorJAK/STAT signalingTEC inhibitorVASIrandomized clinical trialritlecitinibskin depigmentationvitiligo

Substanzen

Janus KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Hôpital Henri Mondor and Université Paris-Est Créteil, EpiDermE - Epidemiology in Dermatology and Evaluation of Therapeutics, Creteil, France. Electronic address: khaled.ezzedine@aphp.fr.
  • Inflammation & Immunology Research Unit, Pfizer, Cambridge, Massachusetts.
  • Inflammation & Immunology Research Unit, Pfizer, Collegeville, Pennsylvania.
  • Consultant to Pfizer, Basking Ridge, New Jersey.
  • Clinical Statistics, Pfizer, Cambridge, Massachusetts.
  • Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.

Förderung

  • Pfizer Inc Centers for Therapeutic Innovation
  • Pfizer

Zitieren

APA

Ezzedine, K., Peeva, E., Yamaguchi, Y., Cox, L. A., Banerjee, A., Han, G., Hamzavi, I., Ganesan, A. K., Picardo, M., Thaçi, D., Harris, J. E., Bae, J. M., Tsukamoto, K., Sinclair, R., Pandya, A. G., Sloan, A., Yu, D., Gandhi, K., Vincent, M. S., & King, B. (2023). Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal of the American Academy of Dermatology, 88(2), 395-403. https://doi.org/10.1016/j.jaad.2022.11.005

Vancouver

Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal of the American Academy of Dermatology. 2023;88(2):395-403. doi:10.1016/j.jaad.2022.11.005

BibTeX
@article{Ezzedine2023,
  author = {Ezzedine, Khaled and Peeva, Elena and Yamaguchi, Yuji and Cox, Lori Ann and Banerjee, Anindita and Han, George and Hamzavi, Iltefat and Ganesan, Anand K and Picardo, Mauro and Thaçi, Diamant and Harris, John E and Bae, Jung Min and Tsukamoto, Katsuhiko and Sinclair, Rodney and Pandya, Amit G and Sloan, Abigail and Yu, Dahong and Gandhi, Kavita and Vincent, Michael S and King, Brett},
  title = {Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial},
  journal = {Journal of the American Academy of Dermatology},
  year = {2023},
  volume = {88},
  number = {2},
  pages = {395--403},
  doi = {10.1016/j.jaad.2022.11.005}
}
Kostenlos starten →